Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitaxentan - Pfizer

Drug Profile

Sitaxentan - Pfizer

Alternative Names: IPI 1040; PF-1228305; Sitaxsentan; Sitaxsentan sodium; TBC 11251; Thelin

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Pfizer
  • Class Antihypertensives; Benzodioxoles; Heart failure therapies; Isoxazoles; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Pulmonary arterial hypertension
  • Discontinued Diastolic heart failure; Kidney disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Dec 2010 Discontinued - Phase-II for Kidney disorders in United Kingdom (PO)
  • 10 Dec 2010 Discontinued - Phase-III for Pulmonary hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top